Lv4
574 积分 2024-11-06 加入
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
5天前
已完结
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
14天前
已完结
Single-cell and spatial transcriptomics: Bridging current technologies with long-read sequencing
27天前
已完结
Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer
1个月前
已完结
Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy
1个月前
已完结
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
1个月前
已完结
Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects
2个月前
已完结
Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2个月前
已完结
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer
2个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2个月前
已完结
皖公网安备34019202002308
